DK1166775T3 - Målrettet liposomgenafgivelse - Google Patents

Målrettet liposomgenafgivelse

Info

Publication number
DK1166775T3
DK1166775T3 DK01123562.9T DK01123562T DK1166775T3 DK 1166775 T3 DK1166775 T3 DK 1166775T3 DK 01123562 T DK01123562 T DK 01123562T DK 1166775 T3 DK1166775 T3 DK 1166775T3
Authority
DK
Denmark
Prior art keywords
gene delivery
targeted liposome
liposome gene
virus
targeted
Prior art date
Application number
DK01123562.9T
Other languages
English (en)
Inventor
Esther H Chang
Liang Xu
Kathleen Pirollo
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of DK1166775T3 publication Critical patent/DK1166775T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DK01123562.9T 1997-11-19 1998-11-19 Målrettet liposomgenafgivelse DK1166775T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6618897P 1997-11-19 1997-11-19
US8317598P 1998-04-27 1998-04-27
EP98958643A EP1032369B1 (en) 1997-11-19 1998-11-19 Targeted liposome gene delivery

Publications (1)

Publication Number Publication Date
DK1166775T3 true DK1166775T3 (da) 2010-05-03

Family

ID=26746455

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01123562.9T DK1166775T3 (da) 1997-11-19 1998-11-19 Målrettet liposomgenafgivelse

Country Status (12)

Country Link
EP (2) EP1166775B1 (da)
JP (2) JP2001522871A (da)
CN (3) CN1904055A (da)
AT (2) ATE295722T1 (da)
AU (1) AU759164C (da)
CA (1) CA2308584C (da)
DE (2) DE69830249T2 (da)
DK (1) DK1166775T3 (da)
ES (1) ES2339421T3 (da)
HK (1) HK1045641B (da)
PT (1) PT1166775E (da)
WO (1) WO1999025320A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
ATE511543T1 (de) 1999-02-22 2011-06-15 Univ Georgetown Immunoliposome mit einem targeting- antikörperfragment zur systemischen genverabreichung
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2004066908A2 (fr) * 2003-01-17 2004-08-12 Sanofi Pasteur Composition comprenant lipides cationiques et un polynucleotide ou un polpeptide et methode pour leur delivrance ciblee
US20040241088A1 (en) * 2003-01-28 2004-12-02 Georgetown University Method for evaluating the efficacy of certain cancer treatments
CN1327899C (zh) * 2003-05-10 2007-07-25 彭朝晖 腺病毒载体与p53基因的基因重组体的应用
PT1633327E (pt) * 2003-06-04 2010-11-08 Univ Georgetown Método para melhoramento da estabilidade e duração de armazenamento de complexos lipossomais
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
WO2007061141A1 (ja) * 2005-11-24 2007-05-31 Genomidea, Inc. 改変パラミクソウイルスおよびその作製方法
MX2008014362A (es) 2006-05-15 2008-11-27 Univ Georgetown Preparacion de inmunoliposomas dirigidos a anticuerpos o a fragmentos de anticuerpos para la administracion sistemica de agentes terapeuticos o de diagnostico y usos de los mismos.
CN102133404B (zh) * 2011-03-23 2013-01-16 成都诺恩生物科技有限公司 一种肿瘤靶向治疗药物载体、其制备方法及其应用
US20130177629A1 (en) 2011-12-22 2013-07-11 Nuvo Research Gmbh Liposomal compositions
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
SG2013014170A (en) 2012-09-19 2014-04-28 Univ Georgetown Targeted liposomes
WO2014159917A2 (en) 2013-03-14 2014-10-02 Georgetown University Treatment for exposure to nerve agent
CA3001054C (en) 2015-10-08 2021-12-14 University Of Utah Research Foundation Elephant p53 proteins and nuleic acids encoding the same for preventing or treating cancer
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
US12274784B2 (en) 2018-10-12 2025-04-15 Synergene Therapeutics, Inc. Methods for reducing side effects of immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
HUT77263A (hu) * 1994-09-13 1998-03-02 Theratech Inc. Kémiai anyagok bejuttatása egy specifikus sejttípus sejtjeinek belsejébe
US20020051767A1 (en) * 1995-09-13 2002-05-02 Yawen L. Chiang Cancer treatment
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
EP0904100B1 (en) * 1996-02-09 2006-07-26 Pi-Wan Cheng Cationic lipid and receptor ligand-facilitated delivery of biologically active molecules
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンb運搬体

Also Published As

Publication number Publication date
CN1616665A (zh) 2005-05-18
EP1032369B1 (en) 2005-05-18
CA2308584A1 (en) 1999-05-27
DE69841536D1 (de) 2010-04-15
JP2001522871A (ja) 2001-11-20
HK1045641A1 (en) 2002-12-06
DE69830249D1 (de) 2005-06-23
DE69830249T2 (de) 2006-05-04
PT1166775E (pt) 2010-04-16
HK1035490A1 (en) 2001-11-30
CN1191094C (zh) 2005-03-02
CN1286630A (zh) 2001-03-07
ATE459340T1 (de) 2010-03-15
AU1464299A (en) 1999-06-07
AU759164B2 (en) 2003-04-10
CN1616665B (zh) 2010-10-06
CA2308584C (en) 2011-07-19
WO1999025320A1 (en) 1999-05-27
JP2010263920A (ja) 2010-11-25
ES2339421T3 (es) 2010-05-20
HK1078608A1 (en) 2006-03-17
EP1166775A3 (en) 2003-06-25
ATE295722T1 (de) 2005-06-15
AU759164C (en) 2007-03-29
CN1904055A (zh) 2007-01-31
HK1045641B (en) 2010-10-29
EP1032369A1 (en) 2000-09-06
EP1166775B1 (en) 2010-03-03
EP1166775A2 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
DK1166775T3 (da) Målrettet liposomgenafgivelse
ATE273320T1 (de) Fusogene liposomen
BR9801027B1 (pt) sistema de distribuiÇço de medicamentos.
NO994837L (no) Intravesikal medikamentavleveringssystem
IS1950B (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
IS5130A (is) Arýlsúlfonýlamínó hýdroxamsýruafleiður, notkun þeirra, ásamt lyfjablöndum
DE69637147D1 (de) Transportproteine und deren verwendungen
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
ID29405A (id) Protein antigen tumor sart-3 yang baru dan peptida-peptida antigen tumornya
EP0666313A3 (en) Telomerase as a target in cancer gene therapy.
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
DE59811071D1 (de) Präparation umfassend Thiolgruppen-haltige Proteine
DE3673436D1 (de) Gene fuer biologisch aktive proteine.
FI971377L (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
DK1140994T3 (da) Ydre overflade-proteiner, gener herfor samt anvendelse deraf
IT1316400B1 (it) Complesso integrale giogo di supporto e imbracatore.
EP1124840A4 (en) GENES AND PROTEINS SPECIFIC TO OVARIES
WO2001009173A3 (fr) Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
RU97115918A (ru) Средство, модифицирующее пролиферацию, функциональную активность и гибель нормальных и опухолевых клеток
EP1041146A4 (en) TUMOR ANTIGEN PROTEIN, ITS GENE AND ITS USE
NO20020604D0 (no) Fremgangsmåte for avlevering av terapeutiske midler ved bruk av en dekstrinlösning
ATE222263T1 (de) Prostata-spezifische antigen inhibitore
杨阳 A Life Cant't Be Killed So Simply—Continuation of The Kitten from Chapter I of Black Boy
ATE55618T1 (de) Gene fuer biologisch aktive proteine.
AU1687201A (en) A recombinant virus killing specifically eb-related tumor, the method for constructing and propagating it and the use thereof